Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.76 |
| ▸ | MAPT | P10636 | 6/20 | 0.59 |
| ▸ | POLB | P06746 | 3/20 | 0.59 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | TARBP2 | Q15633 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28987838 | 0.89 | SMN1; SMN2 (0.80) | SMN1; SMN2MAPTPOLBL3MBTL1HTT | |
| SCHEMBL15272231 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2MAPTPOLBL3MBTL1HTT | |
| SCHEMBL28987826 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2MAPTPOLBKMT2AHPGD | |
| SCHEMBL24987981 | 0.86 | SMN1; SMN2 (0.76) | SMN1; SMN2MAPTPOLBL3MBTL1KMT2A | |
| SCHEMBL28987828 | 0.86 | SMN1; SMN2 (0.95) | SMN1; SMN2MAPTL3MBTL1KMT2ATARBP2 | |
| SCHEMBL28987855 | 0.86 | SMN1; SMN2 (1.00) | SMN1; SMN2MAPTL3MBTL1HTTKMT2A | |
| SCHEMBL28987859 | 0.84 | SMN1; SMN2 (0.72) | SMN1; SMN2MAPTPOLBL3MBTL1HTT | |
| SCHEMBL15912496 | 0.81 | MAPT (0.55) | SMN1; SMN2MAPTPOLBL3MBTL1HTT | |
| SCHEMBL13985253 | 0.81 | SMN1; SMN2 (0.60) | SMN1; SMN2MAPTPOLBL3MBTL1HTT | |
| SCHEMBL28987841 | 0.80 | SMN1; SMN2 (0.73) | SMN1; SMN2MAPTPOLBKMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-24 | — | — | US | disclosed |
| US-11718592-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-08 | — | — | US | disclosed |
| US-11718592-B2 | Oxadiazole derivative | Sumitomo Pharma Co., Ltd. (JP) | 2023-08-08 | — | — | US | disclosed |
| CN-114835656-A | 1,3, 4-oxadiazole ethyl acetate and synthesis method thereof | 天津中医药大学 | 2022-08-02 | — | — | CN | disclosed |
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | INTERMUNE, INC. | 2014-07-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140213538-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS | LPAR1, LPAR2, LPAR5 | SMN1; SMN2 3450/4885MAPT 4564/4885POLB 4247/4885 |
| US-11718592-B2 | Oxadiazole derivative | OXA1L, SCN1A, CACNA1A | SMN1; SMN2 876/4885MAPT 1620/4885POLB 2991/4885 |
| US-20230265061-A1 | OXADIAZOLE DERIVATIVE | OXA1L, SCN1A, CACNA1A | SMN1; SMN2 876/4885MAPT 1620/4885POLB 2991/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.